替格瑞洛在急性心肌梗死经皮冠状动脉介入治疗术后抗血小板治疗中的应用效果

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the application effect of Ticagrelor in antiplatelet therapy after percutaneous coronary intervention(PCI)for acute myocardial infarction.Methods A total of 100 patients with acute myocardial infarction admitted to Xiangzhou District People′s Hospital of Xiangyang city from January 2019 to June 2020 were selected as the research objects,and were divided into observation group and control group according to random number table method,with 50 patients in each group.The observation group received Aspirin+Ticagrelor before and after PCI,and the control group received Aspirin+Clopidogrel before and after PCI.The platelet aggregation rate,liver function,the incidence of adverse reactions and the total incidence of adverse cardiovascular events in two groups were compared.Results There was no significant difference in platelet aggregation rate between the two groups before operation(P>0.05).The platelet aggregation rate of observation group at 2,24 h and 7 d after surgery were lower than those of control group,the differences were statistically significant(P<0.05).There was no significant difference in liver function between the two groups before surgery(P>0.05).The levels of glutamic-oxalacetic transaminase and serum creatinine in the observation group at 7 d after operation were higher than those before operation and those in the control group,the differences were statistically significant(P<0.05).The total incidence of adverse cardiovascular events in observation group was lower than that in control group,the difference was statistically significant(P<0.05).Conclusion Ticagrelor has a significant effect on antiplatelet therapy after PCI in acute myocardial infarction with high safety and is worthy of clinical promotion.In summary,ticagrelor is effective in antiplatelet therapy after PCI for acute myocardial infarction,and it is worthy of clinical application.

Key words： Ticagrelor Acute myocardial infarction Percutaneous coronary intervention Antiplatelet therapy Clopidogrel

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Yan-ling

Cite this article:

WANG Yan-ling. Application effect of Ticagrelor on antiplatelet therapy after percutaneous coronary intervention in acute myocardial infarction[J]. 中国当代医药, 2021, 28(22): 79-82.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I22/79

[1]	常国栋，陈英伟.替格瑞洛在氯吡格雷抵抗急性心肌梗死患者PCI 术后抗血小板治疗中的应用效果[J].中国循证心血管医学杂志，2018，10（4）：466-468.
[2]	张明亮，沈玉华，张立敏，等.替格瑞洛对急性ST 段抬高型心肌梗死急诊经皮冠状动脉介入患者血小板聚集率及QT 离散度的影响[J].中国老年学杂志，2016，36（15）：3667-3669.
[3]	朱甜甜，李春坚，张秋，等.氯毗格雷低反应性与支架内血栓形成的关系[J].江苏医药，2012，38（12）：1401-1403，1364．
[4]	周燕，何泉.不同剂量氯吡格雷对急性心肌梗死患者急诊介入术后血小板聚集率和hs-CRP 水平的影响[J].海南医学院学报，2014，20（7）：923-925，929.
[5]	朱永宏，贾国良，周妙，等.替格瑞洛治疗41 例急性冠状动脉综合征患者的临床疗效[J].中国介入心脏病学杂志，2013，21（6）：374-376.
[6]	韩莹，冯力，李明星，等.替格瑞洛对冠心病血小板药物抵抗患者的治疗作用[J].中国老年学杂志，2014，（9）：2393-2394.
[7]	陈灏珠，钟南山，陆再英．内科学[M].第8 版.北京：人民卫生出版社，2013：242．
[8]	张明亮，沈玉华，王环宇，等.替格瑞洛与氯吡格雷序贯治疗对STEMI 急诊PCI 患者血小板聚集率及MACE 的影响[J].中国循证心血管医学杂志，2016，8（3）：331-334.
[9]	朱兴雷，赵鹏.急性冠脉综合征的发病机制[J].山东医药，2010，50（5）：100．
[10]	张勇，王军，董志军，等.新型抗栓药替格瑞洛对急诊经皮冠状动脉介入治疗的近期疗效及安全性评价[J].中国心血管病研究，2015，12（6）：543-546.
[11]	李阳，于海初.急性心肌梗死经皮冠状动脉介入治疗术后应用替格瑞洛联合阿司匹林治疗发生脑出血一例[J].中国循环杂志，2016，31（12）：1164.
[12]	林佑妮，杨敏，蔡裕福，等.优化后适应术式对急诊经皮冠状动脉介入术急性心肌梗死患者心肌再灌注损伤的影响[J].中国当代医药，2020，27（12）：70-73.
[13]	敬锐，林文华.替格瑞洛在急性心肌梗死患者急诊经皮冠状动脉介入治疗中的应用[J].中国医药，2016，11（9）：1279-1282.
[14]	周嬿.氯吡格雷治疗急性心肌梗死的疗效及近期预后观察[J].中华全科医学，2018，6（12）：1253-1254.
[15]	郭瑞琦，吴迪，周艳秋，等.急性冠脉综合征患者氯吡格雷抵抗的相关影响因素分析[J].中国心血管病研究，2014，12（1）：78-82.
[16]	宋炳慧，王书清，贾珊珊，等.替格瑞洛在急性心肌梗死溶栓后择期冠状动脉介入治疗的临床研究[J].中国临床药理学杂志，2016，32（12）：1066-1068.